Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 2968462, 14 pages
http://dx.doi.org/10.1155/2016/2968462
Research Article

Epigallocatechin-3-gallate Attenuates Renal Damage by Suppressing Oxidative Stress in Diabetic db/db Mice

1Division of Nephrology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gong Wei Road, Shanghai, China
2Division of Nephrology, Shanghai No. 9 People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3The Institutes of Biomedical Sciences (IBS), Fudan University, Shanghai, China
4Hemodialysis Center, Bao Shan Branch of No. 1 People’s Hospital, Shanghai Jiao Tong University, Shanghai, China

Received 22 May 2016; Revised 14 July 2016; Accepted 9 August 2016

Academic Editor: Claudio Cabello-Verrugio

Copyright © 2016 Xiu Hong Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. International Diabetes Federation, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belglum, 7th edition, 2015, http://www.diabetesatlas.org/.
  2. F. A. Hakim and A. Pflueger, “Role of oxidative stress in diabetic kidney disease,” Medical Science Monitor, vol. 16, no. 2, pp. A37–A48, 2010. View at Google Scholar · View at Scopus
  3. S. Tesfaye, L. Vileikyte, G. Rayman et al., “Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management,” Diabetes/Metabolism Research and Reviews, vol. 27, no. 7, pp. 629–638, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. C. Stanton, “Oxidative stress and diabetic kidney disease,” Current Diabetes Reports, vol. 11, no. 4, pp. 330–336, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Gorin and F. Wauquier, “Upstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease,” Molecules and Cells, vol. 38, no. 4, pp. 285–296, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Forbes, M. T. Coughlan, and M. E. Cooper, “Oxidative stress as a major culprit in kidney disease in diabetes,” Diabetes, vol. 57, no. 6, pp. 1446–1454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. E. A. Jaimes, P. Hua, R.-X. Tian, and L. Raij, “Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II, and oxidative stress,” American Journal of Physiology—Renal Physiology, vol. 298, no. 1, pp. F125–F132, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Fukami, S. Ueda, S.-I. Yamagishi et al., “AGEs activate mesangial TGF-β-Smad signaling via an angiotensin II type I receptor interaction,” Kidney International, vol. 66, no. 6, pp. 2137–2147, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Chopra, V. Tiwari, V. Arora, and A. Kuhad, “Sesamol suppresses neuro-inflammatory cascade in experimental model of diabetic neuropathy,” The Journal of Pain, vol. 11, no. 10, pp. 950–957, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M.-L. Brezniceanu, F. Liu, C.-C. Wei et al., “Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells,” Diabetes, vol. 57, no. 2, pp. 451–459, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. H. B. Lee, M.-R. Yu, Y. Yang, Z. Jiang, and H. Ha, “Reactive oxygen species-regulated signaling pathways in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 14, no. 3, pp. S241–S245, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Fang, Y. Jin, H. Zheng et al., “High glucose condition upregulated Txnip expression level in rat mesangial cells through ROS/MEK/MAPK pathway,” Molecular and Cellular Biochemistry, vol. 347, no. 1-2, pp. 175–182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. M. Nam, M. Y. Lee, J. H. Koh et al., “Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property,” Diabetes Research and Clinical Practice, vol. 83, no. 2, pp. 176–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Luo, D.-Z. Dai, Y.-S. Cheng, Q. Zhang, W.-J. Yuan, and Y. Dai, “Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ-injected rats,” Journal of Pharmacy and Pharmacology, vol. 63, no. 7, pp. 943–951, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Xu, D.-Z. Dai, and Y. Dai, “Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in rats,” American Journal of Nephrology, vol. 29, no. 3, pp. 252–256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. H.-J. Jang, S. D. Ridgeway, and J.-A. Kim, “Effects of the green tea polyphenol epigallocatechin-3-gallate on high-fat diet-induced insulin resistance and endothelial dysfunction,” American Journal of Physiology—Endocrinology and Metabolism, vol. 305, no. 12, pp. E1444–E1451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. C. E. N. Reiter, J.-A. Kim, and M. J. Quon, “Green tea polyphenol epigallocatechin gallate reduces endothelin-1 expression and secretion in vascular endothelial cells: roles for AMP-activated protein kinase, Akt, and FOXO1,” Endocrinology, vol. 151, no. 1, pp. 103–114, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. P. Yoon, Y. H. Maeng, R. Hong et al., “Protective effects of epigallocatechin gallate (EGCG) on streptozotocin-induced diabetic nephropathy in mice,” Acta Histochemica, vol. 116, no. 8, pp. 1210–1215, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Gao, Y. Wang, Z. Wu, J. Ming, and G. Zhao, “Interaction of barley β-glucan and tea polyphenols on glucose metabolism in streptozotocin-induced diabetic rats,” Journal of Food Science, vol. 77, no. 6, pp. H128–H134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Elbling, R.-M. Weiss, O. Teufelhofer et al., “Green tea extract and (-)-epigallocatechin-3-gallate, the major tea catechin, exert oxidant but lack antioxidant activities,” The FASEB Journal, vol. 19, no. 7, pp. 807–809, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. G.-X. Li, Y.-K. Chen, Z. Hou et al., “Pro-oxidative activities and dose-response relationship of (−)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro,” Carcinogenesis, vol. 31, no. 5, pp. 902–910, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Yamabe, T. Yokozawa, T. Oya, and M. Kim, “Therapeutic potential of (−)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 1, pp. 228–236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Gu, X. Liu, Q.-X. Wang et al., “Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts,” Experimental Cell Research, vol. 318, no. 16, pp. 2105–2115, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Liu, J. T. Perkins, and B. Hennig, “EGCG prevents PCB-126-induced endothelial cell inflammation via epigenetic modifications of NF-κB target genes in human endothelial cells,” Journal of Nutritional Biochemistry, vol. 28, pp. 164–170, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Peng, T. Ye, D. Rakheja et al., “The green tea polyphenol (−)-epigallocatechin-3-gallate ameliorates experimental immune-mediated glomerulonephritis,” Kidney International, vol. 80, no. 6, pp. 601–611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Yan, Y. Zhao, S. Suo, Y. Liu, and B. Zhao, “Green tea catechins ameliorate adipose insulin resistance by improving oxidative stress,” Free Radical Biology and Medicine, vol. 52, no. 9, pp. 1648–1657, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Pistrosch, J. Passauer, K. Herbrig, U. Schwanebeck, P. Gross, and S. R. Bornstein, “Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy,” Hormone and Metabolic Research, vol. 44, no. 12, pp. 914–918, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Reidy, H. M. Kang, T. Hostetter, and K. Susztak, “Molecular mechanisms of diabetic kidney disease,” The Journal of Clinical Investigation, vol. 124, no. 6, pp. 2333–2340, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Li, G.-S. Shen, C. Yu et al., “Local bone interaction between renin-angiotensin system and kallikrein-kinin system in diabetic rat,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 2, pp. 1604–1612, 2015. View at Google Scholar · View at Scopus
  30. H. Suzuki, T. Kikuta, T. Inoue, and U. Hamada, “Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy,” World Journal of Nephrology, vol. 4, no. 1, pp. 118–126, 2015. View at Publisher · View at Google Scholar
  31. D. A. Long, K. L. Price, J. Herrera-Acosta, and R. J. Johnson, “How does angiotensin II cause renal injury?” Hypertension, vol. 43, no. 4, pp. 722–723, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. J. R. Ingelfinger, “Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes,” The New England Journal of Medicine, vol. 364, no. 10, pp. 970–971, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. P. Lakshmanan, R. A. Thandavarayan, K. Watanabe et al., “Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice,” Molecular and Cellular Endocrinology, vol. 348, no. 1, pp. 104–111, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Kochi, M. Shimizu, D. Terakura et al., “Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions,” Cancer Letters, vol. 342, no. 1, pp. 60–69, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. Y.-S. Han, L. Lan, J. Chu, W.-Q. Kang, and Z.-M. Ge, “Epigallocatechin gallate attenuated the activation of rat cardiac fibroblasts induced by angiotensin II via regulating β-arrestin1,” Cellular Physiology and Biochemistry, vol. 31, no. 2-3, pp. 338–346, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. A. A. Elmarakby and J. C. Sullivan, “Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy,” Cardiovascular Therapeutics, vol. 30, no. 1, pp. 49–59, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Y. Shi, F. Hou, H. X. Niu et al., “Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase,” Endocrinology, vol. 149, no. 4, pp. 1829–1839, 1829. View at Google Scholar